

Supplementary Files_uncropped images
Applied Microbiology and Biotechnology

Chaperna-assisted self-assembly of foot and mouth disease virus-like particles and nanoparticles

Tae Hoon Kim^{1†}, Min Seok Kim^{2†}, Ji Eun Yu³, Beom Jeung Hwang⁴, Jemin Sung^{3,5}, Seong Hyun Park², Hyun Byun⁶, Doda Kim¹, Jeongseok Jeon¹, Gyoonee Han^{1*}, Sanguine Byun^{7*}, Baik-Lin Seong^{4,8*}

¹The Interdisciplinary Graduate Program in Integrative Biotechnology, Yonsei University, Incheon, Republic of Korea

²Graduate Program in Biomaterials Science and Engineering, Yonsei University, Seoul, Republic of Korea

³Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul, 03722, Republic of Korea

⁴Vaccine Innovative Technology ALliance (VITAL)-Korea, Yonsei University, Seoul, Republic of Korea

⁵Vaxdigm Co., Ltd., Seoul, Republic of Korea

⁶Interdisciplinary Program of Integrated OMICS for Biomedical Science, Yonsei University, Seoul, Republic of Korea

⁷Department of Biotechnology, Yonsei University, Seoul 03722, Republic of Korea

⁸Department of Microbiology, Yonsei University College of Medicine, Seoul, Republic of Korea


† The authors contributed equally to the work.

* Corresponding authors.


Correspondence: Gyoonee Han, gyoonee@yonsei.ac.kr; Sanguine Byun, sanguine@yonsei.ac.kr; Baik-Lin Seong, blseong@yonsei.ac.kr

Figure 3. FMDV Antigens Protein Expression Test

a) FMDV VLP Direct Form (VP0/VP1/VP3)



a) FMDV VLP ChaY3-VP0/VP1/VP3




c) LTB-FMDV VP1 Direct Form and ChaY3-LTB-FMDV VP1



Figure 4. FMDV Antigens Nickel Affinity Purification

a) ChaY3/SUMO/MBP-VP0




a) ChaY3/SUMO/MBP-VP1




a) ChaY3/SUMO/MBP-VP3



c) ChaY3/SUMO/MBP-LTB-FMDV VP1



e) FMDV VLP ChaY3-VP0/VP1/VP3



f) ChaY3-LTB-FMDV VP1






Figure 5. Size-exclusion chromatography (SEC) of recombinant FMDV antigens


a) FMDV VLP



b) FMDV VLP (TEV+) (Red Bold Line)



c) CLF




d) CLF (TEV+) (Red Bold Line)



Figure 9. Analysis of RNA interaction of ChaY3


b) ChaY3 Protein Expression Test




a) ChaY3 Nickel Affinity Purification



c) ChaY3-RNA interaction analysis



Agarose gel analysis




Agarose gel Coomassie blue staining



ChaY3 concentrated (Red Bold Line)

Figure S1. TEV protease cleavage efficacy of FMDV constructs

a) ChaY3-VP0/VP1/VP3 TEV cut efficacy




b) ChaY3-LTB-FMDV VP1 TEV cut efficacy




Figure S7. IPTG screening of recombinant FMDV antigens

a) ChaY3-VP0



b) ChaY3-VP1



c) ChaY3-VP3



d) ChaY3-LTB-FMDV VP1




Figure S8. S' fraction comparison of ChaY3/SUMO/MBP-LTB-FMDV VP1

a) ChaY3-LTB-FMDV VP1



b) SUMO-LTB-FMDV VP1



c) MBP-LTB-FMDV VP1

